High‐level expression of ARID1A predicts a favourable outcome in triple‐negative breast cancer patients receiving paclitaxel‐based chemotherapy

Paclitaxel‐based chemotherapy is a common strategy to treat patients with triple‐negative breast cancer (TNBC). As paclitaxel resistance is still a clinical issue in treating TNBCs, identifying molecular markers for predicting pathologic responses to paclitaxel treatment is thus urgently needed. Her...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of cellular and molecular medicine 2018-04, Vol.22 (4), p.2458-2468
Hauptverfasser:	Lin, Yuan‐Feng, Tseng, Ing‐Jy, Kuo, Chih‐Jung, Lin, Hui‐Yu, Chiu, I‐Jen, Chiu, Hui‐Wen
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic Combined Chemotherapy Protocols - pharmacology ARID1A Breast cancer Cell Line, Tumor Chemotherapy Disease-Free Survival DNA-Binding Proteins Drug Resistance, Neoplasm - genetics Female Gene Expression Regulation, Neoplastic - drug effects Humans Indoles - pharmacology Kaplan-Meier Estimate Middle Aged Nuclear Proteins - genetics Original p38 Mitogen-Activated Protein Kinases - genetics p38MAPK Paclitaxel Paclitaxel - administration & dosage Paclitaxel - adverse effects Patients Transcription Transcription Factors - genetics Triple Negative Breast Neoplasms - drug therapy Triple Negative Breast Neoplasms - genetics Triple Negative Breast Neoplasms - pathology triple‐negative breast cancer
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!